Company Overview
Greenwich LifeSciences, Inc. operates as a clinical-stage biopharmaceutical entity focused on developing novel cancer immunotherapies specifically targeting breast cancer and other HER2/neu-expressing malignancies within the United States and Romania. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, a classification that defines its operational environment as high-risk, high-reward research and development driven by regulatory approval pathways rather than immediate product sales. Currently, the organization employs a workforce of four individuals and holds a total market capitalization of $360.08 million. The disparity between this substantial market valuation and the lack of reported annual revenue figures indicates that the company's equity value is derived almost entirely from future clinical trial potential and intellectual property assets rather than current operational cash generation.
Financial Health
The financial statements for Greenwich LifeSciences, Inc. report a Net Income of $-19,475,704 and an EBITDA of $-19,584,400 for the trailing twelve months, while specific revenue figures are not disclosed. The significant gap between the reported Net Income and EBITDA, combined with the absence of positive revenue data, reveals a cost structure dominated by high research and development expenses and clinical trial costs that have not yet been offset by product sales. The company generated Free Cash Flow of $-1,357,228, a metric that signifies the organization is consuming its existing liquidity reserves to fund its clinical programs rather than generating surplus capital for distribution. All three key profitability metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which is characteristic of early-stage biotechnology firms where revenue is either negligible or insufficient to cover the massive fixed costs of drug development. The balance sheet shows a Cash position of $3.81 million with no reported Debt, meaning the Debt to Equity ratio is N/A. This absence of recorded debt suggests the company maintains an un-levered balance sheet, relying exclusively on equity financing to sustain its operations. Additionally, the Current Ratio stands at 2.35, indicating that the company possesses more than double the current assets necessary to cover its short-term liabilities, thereby demonstrating a robust short-term liquidity position despite the cash burn rate. Finally, the Return on Equity is -543.4% and the Return on Assets is -254.2%, figures that mathematically reflect the heavy investment in assets required to achieve future clinical milestones rather than immediate financial returns.
Valuation Assessment
Valuation multiples for Greenwich LifeSciences, Inc. present a unique profile typical of pre-revenue biopharmaceutical companies, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -31.70. The negative forward P/E ratio implies that the market expects the company to generate earnings in the future, as a positive earnings trajectory is required to normalize this metric from its current negative state. The Price to Book ratio is calculated at 164.49, a figure that indicates the market is valuing the company at a significant premium over its net asset book value, likely attributing high value to the potential success of its lead product candidate, GP2. Alternative valuation metrics such as the Price to Sales ratio and EV/EBITDA are listed as N/A and -18.19 respectively; the negative EV/EBITDA confirms that the company's enterprise value is heavily weighted against negative earnings before interest, taxes, depreciation, and amortization. The stock has traded within a 52-week range with a high of $34.10 and a low of $7.78, placing the current trading price in a volatile position relative to this historical range. The Beta value of 1.50 suggests that the stock exhibits higher volatility than the broader market, moving 50% more aggressively than the general market index in response to economic or sector-specific news.
Growth & Income
The reported Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A due to the company's current stage of development and lack of sustained commercial revenue. Since the company is a clinical-stage entity with no material sales, the traditional comparison of earnings growth versus revenue growth is not applicable in the standard sense of expanding a commercial business. As the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that the organization follows a standard biotechnology strategy of reinvesting all available capital back into research, clinical trials, and operational expansion rather than distributing income to shareholders. Consequently, the overall growth and income profile for Greenwich LifeSciences, Inc. is defined entirely by the probability of clinical trial success and the eventual commercial launch of its immunotherapy products, rather than by current cash flow generation or shareholder distributions.